Trial Profile

A Phase Ⅱ Study to Evaluate Efficacy and Safety of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 11 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Camrelizumab (Primary) ; Cyclophosphamide (Primary) ; Epirubicin (Primary) ; Paclitaxel (Primary)
Indications Early breast cancer; Triple negative breast cancer
Focus Therapeutic Use

04 Jun 2024 Results comparing the efficacy, safety and biomarker exploration of camrelizumab combined with chemotherapy and chemotherapy as neoadjuvant treatment for early-stage TNBC, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
13 Sep 2022 Status changed from recruiting to active, no longer recruiting, according to Results presented at the 47th European Society for Medical Oncology Congress.
13 Sep 2022 Results presented at the 47th European Society for Medical Oncology Congress

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com